与肥胖相关的HFpEF中的炎症:STEP-HFpEF计划
Subodh Verma1, Mark C Petrie2, Barry A Borlaug3
1Division of Cardiac Surgery, Li Ka Shing Knowledge Institute of St Michael's Hospital, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada.
Journal of the American College of Cardiology
|September 1, 2024
概括
在患有与肥胖相关的HFpEF的患者中,塞马格卢提德有效地改善了心力衰竭与保存的喷射分数 (HFpEF) 症状,降低了体重和炎症 (C-反应性蛋白),而不考虑基线炎症水平.
科学领域:
- 心脏病学 心脏病学
- 代谢疾病 代谢疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症在与肥胖相关的心力衰竭中发挥着关键作用,具有保存的喷射分数 (HFpEF).
- 在STEP-HFpEF计划中,塞马格卢提德证明了益处,包括症状改善,体重减轻和降低C反应蛋白 (CRP).
- 有限的数据存在于炎症发病率,特征和semaglutide在HFpEF中不同炎症水平的疗效.
研究的目的:
- 描述不同炎症水平 (CRP) 的HFpEF患者的基线特征.
- 评估塞马格卢提德的疗效是否受到HFpEF基线CRP水平的影响.
- 为了确定CRP降低和体重减轻与塞马格卢提德治疗之间的关系.
主要方法:
- 聚合STEP-HFpEF和STEP-HFpEFDM试验数据的二次分析.
- 根据基线CRP水平分层的患者 (<2,≥2至<10,≥10 mg/L).
- 根据基线CRP类别对双重主要终点 (健康状况,体重) 和二次终点 (6MWD,复合) 的评估变化.
主要成果:
- 1145名患者中有71%的CRP升高 (≥2 mg/L);较高的CRP与年轻的年龄,女性性别,较高的BMI,较差的健康状况和较短的6MWD相关.
- 在CRP类别 (P-相互作用不显著) 中,塞马格卢提德持续改善了HF症状,限制,体重,6MWD和复合终点.
- 与安慰剂相比,塞马格卢提德显著降低了CRP水平,无论基线CRP或体重减轻程度如何 (CRP降低的P-相互作用=0.32).
结论:
- 在与肥胖相关的HFpEF中,炎症非常普遍.
- 在所有基线炎症水平上,塞马格卢提德对HF症状,功能和体重提供了一致的好处.
- 塞马格卢提德有效降低HFpEF的炎症,独立于基线CRP或实现的体重减轻.
相关概念视频
01:17Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
404
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
404
01:22Heart Failure Drugs: Diuretics
352
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
352
01:22Heart Failure Drugs: β-Blockers
322
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
322
01:20Exercise and Cardiovascular Response
750
Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
750
01:17Ischemic Heart Disease: Overview
1.2K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.2K